HAEMONETICS CORP - Common Stock (HAE)

Q2 2018 13F Holders as of 30 Jun 2018

Type / Class
Equity / Common Stock
Shares outstanding
47,898,935
Total 13F shares
50,368,130
Share change
-2,359,826
Total reported value
$4,517,192,617
Put/Call ratio
1332%
Price per share
$89.68
Number of holders
289
Value change
-$185,243,709
Number of buys
153
Number of sells
138

Institutional Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q2 2018

As of 30 Jun 2018, HAEMONETICS CORP - Common Stock (HAE) was held by 289 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 50,368,130 shares. The largest 10 holders included BlackRock Inc., VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, Capital Research Global Investors, Neuberger Berman Group LLC, DIMENSIONAL FUND ADVISORS LP, Jackson Square Partners, LLC, and WELLS FARGO & COMPANY/MN. This page lists 289 institutional shareholders reporting positions in this security for the Q2 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.